Biology and management of patients with triple-negative breast cancer

Oncologist

Volumn 21, Issue 9, 2016, Pages 1050-1062

  Sharma, Priyanka ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Cancer biomarkers; Cancer chemotherapy agents; Cancer genetics; Triple negative breast neoplasms

Indexed keywords

ANDROGEN RECEPTOR ANTAGONIST; ANTHRACYCLINE; ATEZOLIZUMAB; AURORA KINASE INHIBITOR; AZACITIDINE; BEVACIZUMAB; BIOLOGICAL MARKER; BUPARLISIB; CARBOPLATIN; CHECKPOINT KINASE INHIBITOR; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; ENZALUTAMIDE; HEAT SHOCK PROTEIN 90 INHIBITOR; IPATASERTIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIVOLUMAB; OLAPARIB; PACLITAXEL; PEMBROLIZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLATINUM; ROMIDEPSIN; TALAZOPARIB; TASELISIB; TAXANE DERIVATIVE; UNINDEXED DRUG; ANGIOGENESIS INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; TUMOR MARKER;

ADJUVANT THERAPY; ARTICLE; BIODIVERSITY; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER STAGING; FEMALE; GENE EXPRESSION REGULATION; GERMLINE MUTATION; HUMAN; LOCAL THERAPY; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMBINATION REPAIR; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; TRIPLE NEGATIVE BREAST CANCER; DNA DAMAGE; DRUG EFFECTS; GENETICS; PATHOLOGY;

ANGIOGENESIS INHIBITORS; BIOMARKERS, TUMOR; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA DAMAGE; FEMALE; GERM-LINE MUTATION; HUMANS; MOLECULAR TARGETED THERAPY; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84988026250     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0067     Document Type: Article

References (131)

1. Bauer KR, Brown M, Cress RD et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007;109:1721-1728.
2. Hammond ME, Hayes DF, Wolff AC et al. American Society Of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract 2010;6:195-197.
3. Wolff AC, Hammond MEH, Hicks DG et al; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31: 3997-4013.
4. Kohler BA, Sherman RL, Howlader N et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst 2015;107:djv048.
5. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13: 2329-2334.
6. Dent R, Trudeau M, Pritchard KI et al. Triplenegative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007;13: 4429-4434.
7. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-1281.
8. Trivers KF, Lund MJ, Porter PL et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009;20: 1071-1082.
9. Millikan RC, Newman B, Tse CK et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008;109:123-139.
10. Livasy CA, Karaca G, Nanda R et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Modern Pathol 2006;19:264-271.
11. Sharma P, Klemp JR, Kimler BF et al. Germline BRCA mutation evaluation in a prospective triplenegative breast cancer registry: Implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat 2014;145:707-714.
12. Gonzalez-Angulo AM, Timms KM, Liu S et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011;17:1082-1089.
13. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-752.
14. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121: 2750-2767.
15. Prat A, Perou CM. De constructing themolecular portraits of breast cancer. Mol Oncol 2011;5:5-23.
16. Shah SP, Roth A, Goya R et al. The clonal and mutational evolution spectrum of primary triplenegative breast cancers. Nature 2012;486:395-399.
17. Bastien RR, Rodríguez-Lescure Á, Ebbert MT et al. PAM50 breast cancer subtyping by RTqPCR and concordance with standard clinical molecular markers. BMCMed Genomics 2012;5:44.
18. Prat A, Adamo B, Cheang MC et al. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. The Oncologist 2013; 18:123-133.
19. Prat A, Parker JS, Karginova O et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
20. Ring BZ, Hout DR, Morris SW et al. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. BMC Cancer 2016;16:143.
21. Stirzaker C, Zotenko E, Song JZ et al. Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusterswith prognostic value. Nat Commun 2015;6:5899.
22. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
23. Leijen S, Schellens JH, Shapiro G et al. A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol 2010.
24. Hartman AR, Kaldate RR, Sailer LM et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 2012;118:2787-2795.
25. Cheang MC, Voduc D, Bajdik C et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14:1368-1376.
26. Dent R, Hanna WM, Trudeau M et al. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 2009;115:423-428.
27. Swain SM, Baselga J, Kim SB et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl JMed 2015;372:724-734.
28. Couch FJ, Hart SN, Sharma P et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 2015;33:304-311.
29. Senkus E, Kyriakides S, Penault-Llorca F et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2013;24(suppl 6):67-83.
30. Coates AS, Winer EP, Goldhirsch A et al. Tailoring therapies-improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol 2015;26:1533-1546.
31. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): breast cancer. 2014. Available at http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.
32. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374.
33. Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006;24:5652-5657.
34. Tan DS, Marchió C, Jones RL et al. Triple negative breast cancer: Molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008;111:27-44.
35. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11:5678-5685.
36. Loi S, Sirtaine N, Piette F et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013;31:860-867.
37. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHer trial. Ann Oncol 2014;25:1544-1550.
38. Adams S, Gray RJ, Demaria S et al. Prognostic value of tumor-infiltrating lymphocytes in triplenegative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014;32:2959-2966.
39. Dieci MV, Criscitiello C, Goubar A et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study. Ann Oncol 2015;26:1518.
40. Salgado R, Denkert C, Demaria S et al. The evaluation of tumor-infiltrating lymphocytes (tils) in breast cancer: Recommendations by an international TILS working group 2014. Ann Oncol 2015;26:259-271.
41. Hatzis C, Pusztai L, Valero V et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 2011;305:1873-1881.
42. Ayers M, Symmans WF, Stec J et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004;22:2284-2293.
43. Gianni L, Zambetti M, Clark K et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005;23:7265-7277.
44. Connor CS, Kimler BF, Mammen JM et al. Impact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast cancer. J Surg Oncol 2015;111:198-202.
45. Golshan M, Cirrincione CT, Sikov WM et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breastconserving surgery and breast conservation rates: Surgical results fromCALGB40603(Alliance). AnnSurg 2015;262:434-439; discussion 438-439.
46. Swain SM, Tang G, Geyer CE Jr et al. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: The NSABP B-38 trial. J Clin Oncol 2013;31:3197-3204.
47. Yardley DAB, Bosserman LD, Keaton MR et al. TITAN: Phase III study ofdoxorubicin/cyclophosphamide (AC) followed by ixabepilone (Ixa) or paclitaxel (Pac) in early-stage, triple-negative breast cancer (TNBC). J Clin Oncol 2015;33:1000a.
48. Wolfgang J, Schneeweiss A, Haeberle A et al. Adjuvant gemcitabine for high-risk breast cancer (BC) patients:Final survival resultsof therandomized phase III SUCCESS-A study. J Clin Oncol 2014;32:1010a.
49. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl JMed 2007;357:2666-2676.
50. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-3247.
51. Robert NJ, Diéras V, Glaspy J et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-1260.
52. Rossari JR, Metzger-Filho O, Paesmans M,et al. Bevacizumab and breast cancer: A meta-analysis of first-line phase III studies and a critical reappraisal of available evidence. J Oncol 2012;2012:417-673.
53. Brufsky A, Valero V, Tiangco B et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: Subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 2012; 133:1067-1075.
54. Baselga J, Segalla JG, Roch´eHet al. Sorafenib in combination with capecitabine: An oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 2012;30: 1484-1491.
55. Miller K, O’Neill AM, Dang CT et al. Bevacizumab (Bv) in the adjuvant treatment of HERr2-negative breast cancer: Final results fromEasternCooperative Oncology Group E5103. J Clin Oncol 2014;32:500a.
56. Cameron D, Brown J, Dent R et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): Primary results of a randomised, phase 3 trial. Lancet Oncol 2013;14:933-942.
57. Prat A, Cruz C, Hoadley KA et al. Molecular features of the basal-like breast cancer subtype based on BRCA1mutation status. Breast Cancer Res Treat 2014;147:185-191.
58. Lips EH, Mulder L, Oonk A et al. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer 2013;108:2172-2177.
59. Kolarić K, Roth A, Jelicic I et al. Phase II clinical trial of cis dichlorodiammine platinum (Cis DDP) in metastatic brain tumors. J Cancer Res Clin Oncol 1982;104:287-293.
60. Sledge GW Jr., Loehrer PJ Sr, Roth BJ et al. Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 1988;6:1811-1814.
61. Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28:1145-1153.
62. Santarosa M, Del Col L, Tonin E et al. Premature senescence is amajor response toDNAcross-linking agents in BRCA1-defective cells: Implication for tailoredtreatments ofBRCA1mutation carriers. Mol Cancer Ther 2009;8:844-854.
63. Byrski T, Dent R, Blecharz Petal. Resultsof aphase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012;14:R110.
64. Hurley J, Reis IM, Rodgers SE et al. The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: Retrospective analysis of 144 patients. Breast Cancer Res Treat 2013;138:783-794.
65. Tutt A, Ellis P, Kilburn L et al. The TNT trial: A randomized phase III trial of carboplatin (C) comparedwith docetaxel (D) for patients withmetastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). J Cancer Res 2015;75:S3-01.
66. von Minckwitz G, Blohmer JU, Costa SD et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2013;31:3623-3630.
67. Sharma PS, Stecklein S, Kimler BF et al. BRCA1 insufficiency is predictive of superior survival in patients with triple negative breast cancer treated with platinum based chemotherapy. Cancer Res 2012;72:PD09-02.
68. Telli ML, Jensen KC, Vinayak S et al. Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: Precog 0105. J Clin Oncol 2015;33:1895-1901.
69. Isakoff SJ, Mayer EL, He L et al. Tbcrc009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triplenegative breast cancer. J Clin Oncol 2015;33:1902-1909.
70. Sikov WM, Berry DA, Perou C M et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015;33:13-21.
71. von Minckwitz G, Schneeweiss A, Loibl S et al. Neoadjuvant carboplatin in patients with triplenegative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol 2014;15:747-756.
72. Tamura K, Hashimoto J, Tsuda H et al. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/ epirubicin/5-fluorouracil asneoadjuvant chemotherapy for stage II/IIIia HER2-negative breast cancer. J Clin Oncol 2014;32:1017a.
73. Gluz O, Nitz U, Liedtke C et al. Comparison of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. Cancer Res 2016;15:S6-07.
74. Kern P, Kalisch A, Kolberg HC et al. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, earlystage breast cancer: A multicentric analysis of feasibility and rates of pathologic complete response. Chemotherapy 2013;59:387-394.
75. Wang J, Xu B, Li Q et al. Differential response of neoadjuvant chemotherapy with taxane-carboplatin versus taxane-epirubicin in patients with locally advanced triple-negative breast cancer. J Clin Oncol 2014;32:1105a.
76. Sharma P, Stecklein SR, Kimler BF et al. Efficacy of neoadjuvant carboplatin/docetaxel chemotherapy in sporadic and BRCA-associated triple-negative breast cancer (TNBC). J Clin Oncol 2014;32:1022a.
77. Sikov WM, Berry DA, Perou CM et al. Eventfree and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC 1/2 carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance). Cancer Res 2016;76:S2-05
78. Von Minckwitz G, Loibl S, Schneeweiss A et al. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvanttherapyfortriple- negativeandHER2-positiveearly breast cancer (GeparSixto). Presented at the 2015 San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. Abstract S2-04.
79. Stecklein SR, Sharma P. Tumor homologous recombination deficiency assays: Another step closer to clinical application? Breast CancerRes 2014;16:409.
80. Sharma P, Stecklein SR, Kimler BF et al. The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer. J Cancer Ther Res 2014;3:1-11.
81. Mulligan JM, Hill LA, Deharo S et al. Identification and validation of an anthracycline/cyclophosphamidebased chemotherapy response assay in breast cancer. J Natl Cancer Inst 2014;106:djt335.
82. Watkins J, Weekes D, Shah V et al. Genomic complexity profiling reveals that hormad1 overexpression contributes to homologous recombination deficiency in triple-negative breast cancers. Cancer Discov 2015;5:488-505.
83. Timms KM, Abkevich V, Neff C et al. Association between BRCA1/2 status and DNA-based assays for homologous recombination deficiency in breast cancer. Cancer Res 2013;suppl 73:P6-05-10.
84. Sharma P, Khan QJ, Kimler BF et al. Results of a phase II study of neoadjuvant platinum/taxane based chemotherapy and erlotinib for triple negative breast cancer. Cancer Res 2010;70:P1-11-07.
85. Abkevich V, Timms KM, Hennessy BT et al. Patterns of genomic loss of heterozygosity predict homologous recombinationrepair defects inepithelial ovarian cancer. Br J Cancer 2012;107:1776-1782.
86. Von Minckwitz GH, Hahnen E, Fasching PA et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results fromGeparSixto. J Clin Oncol 2014;32:1005a.
87. Vollebergh MA, Lips EH, Nederlof PM et al. Genomic patterns resembling BRCA1- and BRCA2- mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res 2014;16:R47.
88. Lips EH, Mulder L, Hannemann J et al. Indicatorsof homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann Oncol 2011;22:870-876.
89. Keir ME, Butte MJ, Freeman GJ et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704.
90. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-264.
91. Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One 2014;9:e88557.
92. Ghebeh H, Mohammed S, Al-Omair A et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important highrisk prognostic factors. Neoplasia 2006;8:190-198.
93. Nanda R, Chow LQ, Dees EC et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Cancer Res 2015;75:S1-09.
94. Emens LA, Braiteh FS, Cassier P et al. Inhibition of PD-l1 by MPDL3280A leads to clinical activity in patients with metastatic triple- negative breast cancer. Cancer Res 2015;75:PD1-6.
95. Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-251.
96. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-917.
97. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-921.
98. Fong PC, Boss DS, Yap T A et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl JMed 2009;361:123-134.
99. Tutt A, Robson M, Garber JE et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 2010;376:235-244.
100. Kaufman B, Shapira-Frommer R, Schmutzler RK et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33:244-250.
101. Sandhu SK, Schelman WR, Wilding G et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 2013;14:882-892.
102. Lea M. Bmn673 is a PARP inhibitor in clinical development for the treatment of breast cancer patients with deleterious germline brca1 and 2 mutations. Paper presented at: San Antonio Breast Cancer Symposium; December 10-14, 2013; San Antonio, TX.
103. Pahuja SB, Beumer JH, Appleman LJ et al. Outcome of BRCA 1/2-mutated (BRCA1) and triplenegative, BRCA wild type (BRCA-wt) breast cancer patients in a phase i study of single-agent veliparib (V). J Clin Oncol 2014;32:135a.
104. Gewinner C, Wang ZC, Richardson A et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009;16:115-125.
105. Marty B, Maire V, Gravier E et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 2008;10:R101.
106. Fedele CG, Ooms LM, Ho M et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/ Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci USA 2010;107:22231-22236.
107. Ibrahim YH, García-García C, Serra V et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2012;2:1036-1047.
108. Juvekar A, Burga LN, Hu H et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2012;2:1048-1063.
109. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421:499-506.
110. Adimoolam S, Sirisawad M, Chen J et al. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci USA 2007;104:19482-19487.
111. Botrugno OA, Robert T, Vanoli F et al. Molecular pathways: Old drugs define new pathways: Non-histone acetylation at the crossroads of the DNA damage response and autophagy. Clin Cancer Res 2012;18:2436-2442.
112. Brazelle W, Kreahling JM, Gemmer J et al. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS One 2010;5: e14335.
113. Munshi A, Kurland JF, Nishikawa T et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 2005;11:4912-4922.
114. Zhang J, Powell SN. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res 2005;3:531-539.
115. Stecklein SR, Kumaraswamy E, Behbod F et al. BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation. Proc Natl Acad Sci USA 2012;109:13650-13655.
116. Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008;410:439-453.
117. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/ hsp70-based chaperone machinery. Exp Biol Med (Maywood) 2003;228:111-133.
118. Peng G, Chun-Jen Lin C, Mo W et al. Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat Commun 2014;5:3361.
119. Bhalla KN, Rao R, Das Gupta S et al. Treatment with histone deacetylase inhibitors creates ‘BRCAness’ and sensitizes human triple negative breast cancer cells to PARP inhibitors and cisplatin. Cancer Res 2012;72(suppl 24):S3-S7.
120. Weberpals JI, O’Brien AM, Niknejad N et al. The effect of the histone deacetylase inhibitorM344 on BRCA1 expression in breast and ovarian cancer cells. Cancer Cell Int 2011;11:29.
121. Ha K, Fiskus W, Choi DS et al. Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget 2014;5:5637-5650.
122. Gucalp A, Traina TA. Triple-negativebreastcancer: role of the androgen receptor. Cancer J 2010;16:62-65.
123. Farmer P, Bonnefoi H, Becette V et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005;24:4660-4671.
124. Doane AS, Danso M, Lal P et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional programand response toandrogen.Oncogene, 2006;25:3994-4008.
125. Loibl S, Müller BM, von Minckwitz G et al. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2011;130:477-487.
126. Masuda H, Baggerly KA, Wang Y et al. Differential responseto neoadjuvantchemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013;19:5533-5540.
127. Gucalp A, Tolaney S, Isakoff SJ et al. Phase II trial of bicalutamide in patients with androgen receptorpositive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res 2013;19:5505-5512.
128. Traina TA, Miller K, Yardley DA et al. Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR1 triple-negative breast cancer (TNBC). J Clin Oncol 2015;33:1003a.
129. Parker JS, Peterson AC, Tudor IC, Hoffman J, Uppal H et al. A novel biomarker to predict sensitivity to enzalutamide (ENZA) in TNBC. J Clin Oncol, 2015;33:1083a.
130. Alba E, Calvo L, Albanell J et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: Results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol 2012;23:3069-3074.
131. Rugo HS, Olopade O, De Michele A et al. Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the i-spy2 trial. Cancer Res 2013;73:S5-02